Your browser is no longer supported. Please, upgrade your browser.
Settings
KERX Keryx Biopharmaceuticals, Inc. daily Stock Chart
KERX [NASD]
Keryx Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.82 Insider Own0.70% Shs Outstand120.45M Perf Week-0.34%
Market Cap348.11M Forward P/E- EPS next Y-0.08 Insider Trans-2.42% Shs Float118.93M Perf Month-10.25%
Income-97.90M PEG- EPS next Q-0.12 Inst Own62.30% Short Float13.94% Perf Quarter-7.07%
Sales81.20M P/S4.29 EPS this Y6.20% Inst Trans-0.41% Short Ratio20.01 Perf Half Y-50.34%
Book/sh-0.34 P/B- EPS next Y87.10% ROA-105.00% Target Price6.67 Perf Year-40.17%
Cash/sh0.41 P/C7.03 EPS next 5Y- ROE833.10% 52W Range2.74 - 5.98 Perf YTD-37.85%
Dividend- P/FCF- EPS past 5Y-32.20% ROI-90.50% 52W High-51.67% Beta2.36
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin58.50% 52W Low5.47% ATR0.23
Employees210 Current Ratio2.30 Sales Q/Q70.20% Oper. Margin- RSI (14)46.12 Volatility9.67% 7.43%
OptionableYes Debt/Eq- EPS Q/Q76.70% Profit Margin- Rel Volume1.60 Prev Close3.24
ShortableYes LT Debt/Eq- EarningsNov 08 AMC Payout- Avg Volume828.41K Price2.89
Recom2.30 SMA20-4.76% SMA50-7.16% SMA200-30.32% Volume1,325,329 Change-10.80%
Nov-12-18Downgrade Raymond James Outperform → Mkt Perform
May-08-17Reiterated Maxim Group Buy $7 → $9
Jan-11-17Upgrade Citigroup Sell → Neutral
Nov-09-16Upgrade Maxim Group Hold → Buy $7
Aug-02-16Downgrade Stifel Buy → Hold
Aug-02-16Downgrade FBR Capital Outperform → Mkt Perform $16 → $7
Aug-02-16Downgrade Brean Capital Buy → Hold
Aug-01-16Downgrade Maxim Group Buy → Hold
Jul-08-16Reiterated Maxim Group Buy $7 → $9
Mar-30-16Reiterated FBR Capital Outperform $10 → $13
Feb-29-16Upgrade FBR Capital Mkt Perform → Outperform $10
Feb-26-16Upgrade Raymond James Mkt Perform → Outperform
Feb-26-16Reiterated Stifel Buy $10 → $9
Feb-26-16Downgrade JP Morgan Overweight → Neutral
Feb-25-16Reiterated Maxim Group Buy $11 → $5
Oct-05-15Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-09-15Initiated Raymond James Mkt Perform
Sep-03-15Initiated Citigroup Sell
Aug-13-15Initiated Morgan Stanley Underweight $3
Aug-11-15Initiated FBR Capital Mkt Perform $10
Nov-12-18 01:20PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Keryx Biopharmaceuticals, Inc. (KERX) ACCESSWIRE -10.80%
Nov-09-18 02:29PM  Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Keryx Biopharmaceuticals, Inc. In The U.S. District Court For The District Of Delaware PR Newswire +6.93%
02:23PM  Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag Zacks
05:05AM  Keryx Biopharma: 3Q Earnings Snapshot Associated Press
Nov-08-18 04:30PM  Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results GlobeNewswire
Nov-06-18 04:30PM  Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018 GlobeNewswire
Nov-05-18 08:00PM  Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Keryx Biopharmaceuticals, Inc. In The U.S. District Court For The District Of Delaware PR Newswire
Nov-01-18 03:37PM  Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp. PR Newswire
Oct-30-18 05:31PM  Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics GlobeNewswire
Oct-09-18 07:35AM  New Research Coverage Highlights ICF International, Enphase Energy, Paramount Group, Philip Morris International, Martin Midstream Partners, and Keryx Biopharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-08-18 05:45PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Keryx Biopharmaceuticals, Inc. - KERX ACCESSWIRE
Oct-02-18 04:07PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Keryx Biopharmaceuticals, Inc. Merger Business Wire
09:47AM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Keryx Biopharmaceuticals, Inc. - KERX PR Newswire
Oct-01-18 09:16AM  Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference GlobeNewswire -6.47%
Sep-10-18 09:00AM  Kaskela Law LLC Announces Investigation of Keryx Biopharmaceuticals, Inc. on Behalf of Stockholders - KERX ACCESSWIRE
Sep-05-18 01:35AM  Here's Why Keryx Biopharmaceuticals Dropped 19.6% in August Motley Fool
Aug-17-18 11:31PM  Edited Transcript of KERX earnings conference call or presentation 8-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-09-18 11:57AM  Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag Zacks -6.35%
Aug-08-18 09:12AM  Keryx (KERX) Loss Wider Than Expected in Q2, Sales Miss Zacks -5.26%
07:00AM  Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results GlobeNewswire
06:00AM  Keryx Biopharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 04:05PM  Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018 GlobeNewswire
Jul-30-18 02:00PM  7 Health Care Stocks to Buy for Robust Returns Kiplinger +7.25%
Jul-24-18 08:59AM  Is a Beat in Store for Keryx (KERX) This Earnings Season? Zacks
Jul-19-18 03:08PM  5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates Zacks
Jul-11-18 07:20AM  Free Technical Research on Intrexon and Three More Biotech Equities ACCESSWIRE
Jul-06-18 03:07PM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. is Fair to Shareholders GlobeNewswire
Jul-05-18 06:17PM  Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More Zacks
02:02PM  KERYX BIOPHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger Business Wire
Jul-02-18 11:27AM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Jun-29-18 07:12PM  WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc. PR Newswire
09:08AM  Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall Zacks
Jun-28-18 11:21AM  Here's Why Keryx Biopharmaceuticals and Akebia Therapeutics Are Plunging Today Motley Fool -18.97%
07:00AM  Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease Business Wire
Jun-20-18 09:21AM  Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on Thursday, June 21st GlobeNewswire
Jun-11-18 01:59AM  Why is Keryx (KERX) Down 2.7% Since its Last Earnings Report? Zacks
May-30-18 07:50AM  Wired News Keryx Biopharmaceuticals Shares Results of Clinical Trial for Treating Patients with Advanced Chronic Kidney Disease with Ferric Citrate ACCESSWIRE
May-29-18 06:00PM  Keryx Pharmaceuticals Announces Upcoming Investor Presentations GlobeNewswire
May-25-18 07:21AM  Keryx Biopharmaceuticals Inc (NASDAQ:KERX): Does The Earnings Decline Make It An Underperformer? Simply Wall St.
06:00AM  Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chronic Kidney Disease in a Late-Breaking Presentation at the 55th Annual ERA/EDTA Today in Copenhagen GlobeNewswire
May-15-18 09:41AM  Edited Transcript of KERX earnings conference call or presentation 10-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-11-18 05:09PM  Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat Zacks +5.71%
06:59AM  Market Sentiment Around Loss-Making Keryx Biopharmaceuticals Inc (NASDAQ:KERX) Simply Wall St.
May-10-18 10:19AM  Keryx (KERX) Posts Narrower Than Expected Q4 Loss, Sales Beat Zacks
08:06AM  Keryx Biopharma: 1Q Earnings Snapshot Associated Press
07:00AM  Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results GlobeNewswire
May-08-18 06:24PM  What's in Store for Endocyte (ECYT) This Earnings Season? Zacks
05:45PM  5 Biotech Stocks Set to Beat Estimates This Earnings Season Zacks
May-07-18 07:30AM  Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2018 Financial Results on Thursday, May 10, 2018 GlobeNewswire
Apr-30-18 08:00AM  Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue GlobeNewswire -7.32%
Apr-26-18 10:02AM  What's in the Offing for Keryx (KERX) This Earnings Season? Zacks +5.42%
Apr-19-18 09:00AM  Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress GlobeNewswire
Apr-16-18 08:10AM  Recent Analysis Shows Urban Outfitters, Depomed, Helios and Matheson Analytics, Keryx Biopharmaceuticals, Cloudera, and Valero Energy Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-12-18 08:00AM  Todays Research Reports on Stocks to Watch: Keryx Biopharmaceuticals and CymaBay Therapeutics ACCESSWIRE
Apr-11-18 09:11AM  Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation GlobeNewswire +10.27%
Apr-04-18 08:00AM  Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology GlobeNewswire
Mar-09-18 08:20AM  Report: Exploring Fundamental Drivers Behind Cenovus Energy, Depomed, Zoe's Kitchen, NetApp, Keryx Biopharmaceuticals, and Ocular Therapeutix New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-06-18 07:30AM  Keryx Biopharmaceuticals to Webcast its Presentation at the Cowen 38th Annual Healthcare Conference on March 12, 2018 GlobeNewswire
Mar-05-18 08:40AM  Options Traders Expect Huge Moves in Keryx (KERX) Stock Zacks
Feb-21-18 06:48PM  Keryx Biopharmaceuticals Inc (KERX) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
Feb-13-18 09:00AM  Is the Options Market Predicting a Spike in Keryx (KERX) Stock? Zacks
Feb-08-18 09:49AM  Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down Zacks
07:10AM  Free Post Earnings Research Report: Illuminas Quarterly Revenue Surged 26%; Non-GAAP EPS Soared 69.4% ACCESSWIRE
04:12AM  Edited Transcript of KERX earnings conference call or presentation 7-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
Feb-07-18 10:35AM  Keryx Biopharma reports 4Q loss Associated Press -9.29%
08:37AM  Keryx (KERX) Posts Wider Q4 Loss, Sales Beat, Shares Down Zacks
07:00AM  Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-05-18 10:05AM  Keryx (KERX) Warming Up to Q4 Earnings: What's in Store? Zacks
Feb-02-18 04:05PM  Keryx Biopharmaceuticals to Host Conference Call of Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 7, 2018 GlobeNewswire
Jan-15-18 08:10AM  Todays Research Reports on Trending Tickers: Keryx Biopharmaceuticals and Alder BioPharmaceuticals ACCESSWIRE
Jan-09-18 08:32AM  Implied Volatility Surging for Keryx Biopharmaceuticals (KERX) Stock Options Zacks
Dec-22-17 11:42AM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : December 22, 2017 Capital Cube
09:05AM  Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgans 36th Annual Healthcare Conference on January 10, 2018 GlobeNewswire
Dec-11-17 02:00PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : December 11, 2017 Capital Cube
Dec-10-17 07:16PM  2018 Is a Critical Year for These 3 Small Commercial-Stage Biotech Stocks Motley Fool
Nov-30-17 02:03PM  ETFs with exposure to Keryx Biopharmaceuticals, Inc. : November 30, 2017 Capital Cube
Nov-29-17 08:52AM  Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
08:30AM  Consolidated Research: 2018 Summary Expectations for Schlumberger N.V, W.W. Grainger, Best Buy Co., Acadia Realty Trust, Keryx Biopharmaceuticals, and Gannett Co. Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-27-17 08:30AM  Are Options Traders Betting on a Big Move in Keryx (KERX) Stock? Zacks
Nov-14-17 02:36PM  Keryx Biopharma Down 17% Despite Drug Approval Motley Fool
Nov-13-17 08:20AM  Todays Research Reports on Trending Tickers: Keryx Biopharmaceuticals and ZIOPHARM Oncology ACCESSWIRE
Nov-10-17 12:41PM  Edited Transcript of KERX earnings conference call or presentation 7-Nov-17 1:00pm GMT Thomson Reuters StreetEvents
Nov-09-17 11:52AM  Healthcare: Is Valeant Pharmaceuticals the Turnaround Story of the Century? Motley Fool
11:46AM  Keryx Biopharmaceuticals: This Analyst Blames Slowing Script Growth for Bad Q3 Outcome SmarterAnalyst
08:28AM  Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted Zacks
07:00AM  Corporate News Blog Keryx Announces FDA Approval of Auryxia for Treatment of Iron Deficiency Anemia Patients with Chronic Kidney Disease ACCESSWIRE
Nov-08-17 04:16PM  Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017 GlobeNewswire
11:50AM  Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines Zacks
08:01AM  Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise Motley Fool
Nov-07-17 09:25AM  Keryx (KERX) Posts Wider Q3 Loss, Lags Sales, Shares Down Zacks -17.34%
08:01AM  Keryx Biopharmaceuticals (KERX) Announces FDA Approval of Auryxia Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis; Shares Tumble SmarterAnalyst
07:35AM  Keryx Biopharma reports 3Q loss Associated Press
07:01AM  U.S. FDA Approves Auryxia® (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis GlobeNewswire
07:00AM  Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 04:31PM  Keryx Biopharmaceuticals Moves Third Quarter 2017 Financial Results Call to Tuesday, November 7, 2017 at 8:00 a.m. ET GlobeNewswire
01:58PM  Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter Motley Fool
10:59AM  Only a handful of stocks are driving the stock market rallyagain Yahoo Finance Video
09:10AM  Keryx Biopharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
09:00AM  Keryx Biopharmaceuticals (KERX) in Focus: Stock Moves 10.8% Higher Zacks
08:09AM  The Zacks Analyst Blog Highlights: Keryx Biopharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Heron Therapeutics and Ultragenyx Pharmaceutical Zacks
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holmes Scott AChief Financial OfficerOct 29Sale3.071,2543,850164,111Oct 30 04:07 PM
Neylan John F.Chief Medical OfficerOct 29Sale3.071,2533,847149,435Oct 30 04:07 PM
Carberry Christine A.Chief Operating OfficerOct 18Sale3.292,0406,712111,115Oct 22 08:50 AM
Neylan John F.Chief Medical OfficerAug 15Sale3.041,1863,605150,688Aug 16 07:10 AM
Holmes Scott AChief Financial OfficerAug 15Sale3.041,1853,602165,365Aug 16 07:11 AM
Holmes Scott AChief Financial OfficerJul 30Sale3.862,3549,086166,550Jul 31 04:34 PM
Neylan John F.Chief Medical OfficerJul 30Sale3.861,2824,949151,874Jul 31 04:34 PM
Carberry Christine A.Chief Operating OfficerJul 18Sale4.492,0219,074113,155Jul 19 05:09 PM
Cameron Kevin JDirectorJun 18Sale4.981,6678,302176,666Jun 19 04:13 PM
Cameron Kevin JDirectorJun 15Option Exercise0.4810,0004,800178,333Jun 18 06:39 PM
GILMAN STEVEN CDirectorJun 11Sale5.121,3346,83017,333Jun 12 04:01 PM
Cameron Kevin JDirectorMay 29Sale5.221,6678,702168,333May 31 04:20 PM
GILMAN STEVEN CDirectorMay 29Sale5.221,3336,95818,667May 31 04:19 PM
Neylan John F.Chief Medical OfficerMay 15Sale5.691,1586,589153,156May 16 04:40 PM
Holmes Scott AChief Financial OfficerMay 15Sale5.691,1586,589168,904May 16 04:40 PM
Holmes Scott AChief Financial OfficerApr 30Sale4.672,40711,241170,062May 01 04:16 PM
Neylan John F.Chief Medical OfficerApr 30Sale4.671,3116,122154,314May 01 04:14 PM
Neylan John F.Chief Medical OfficerApr 23Sale4.591,1115,099155,625Apr 24 04:29 PM
Carberry Christine A.Chief Operating OfficerApr 18Sale4.832,0269,786115,176Apr 20 04:11 PM
Holmes Scott AChief Financial OfficerFeb 15Sale4.815,65127,181131,219Feb 16 04:05 PM
Adams BrianGeneral Counsel and SecretaryFeb 15Sale4.815,65227,186126,069Feb 16 04:04 PM
Neylan John F.Chief Medical OfficerFeb 15Sale4.815,65227,186115,486Feb 16 04:04 PM
Madison GregPresident and CEOFeb 15Sale4.8115,31873,680414,086Feb 16 04:04 PM
Holmes Scott AChief Financial OfficerJan 29Sale4.812,83013,612136,870Jan 31 05:19 PM
Adams BrianGeneral Counsel and SecretaryJan 29Sale4.811,5417,412131,721Jan 31 05:18 PM
Neylan John F.Chief Medical OfficerJan 29Sale4.811,5417,412121,138Jan 31 05:19 PM
Neylan John F.Chief Medical OfficerJan 23Sale4.921,3226,504122,679Jan 24 04:16 PM
Carberry Christine A.Chief Operating OfficerJan 18Sale4.879,04844,06475,952Jan 22 08:22 AM
Adams BrianGeneral Counsel and SecretaryJan 05Sale4.697533,532133,262Jan 08 06:06 PM
Madison GregPresident and CEOJan 05Sale4.691,0675,004367,620Jan 08 06:06 PM